No Data
No Data
HK Stocks Buzz | MGM China Holdings Ltd-B (01952) rose over 4%. Natco Pharma Ltd's supplemental application for Nephrotic Syndrome was formally accepted by the National Medical Products Administration. IgA Nephropathy has a potentially high market space.
Yunding Xinyao-B (01952) rose over 4%, as of press time, up 4.23%, reported at HKD 20.45 with a turnover of 15.7881 million Hong Kong dollars.
Everest Medicines Limited's (HKG:1952) Market Cap Dropped HK$542m Last Week; Retail Investors Bore the Brunt
HK stocks surged | Genting Hong Kong -B (01952) rose more than 5%. The potential market space for IgA nephropathy is high, and institutions are bullish on the company's product sales revenue.
Zhītōng finance app learned that Genting New Dawn-B (01952) rose more than 5%, and as of press time, it rose 5.21% to HK$21, with a turnover of HK$29.6038 million. On the news front, Genting New Dawn recently announced that the company showcased Nephoxil's treatment advantages and explored new strategies for IgA nephropathy treatment at the 22nd APSCN and the 44th KSN congress. It is reported that Nephoxil will be used in Boao, Hainan in 2023, and will be approved for listing in China and Macau in December 2023 with sales revenue of 21 million yuan. In addition, Genting New Dawn announced last month that Nephoxil will be used in China's first
Everest Medicines (HKG:1952) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway
Changes in Hong Kong stocks | Genting Xinyao B (01952) rose more than 6% in the afternoon, and the first prescription for the new nephropathy drug, Tolifukang, was launched in mainland China
Genting Xinyao B (01952) rose more than 6% in the afternoon. As of press release, it had risen 5.46% to HK$24.15, with a turnover of HK$74.9047 million.
[Broker Focus] BOC International's first purchase rating for 5 biotech companies indicates that it is firmly optimistic about the sector's potential for heavy snow
Jinwu Financial News | BOC International released an in-depth report on the biotechnology industry. In 2024, the State Council government work report first proposed speeding up the development of the innovative pharmaceutical industry, building new types of productivity such as biomantry, and encouraging entrepreneurship and equity investment. The bank believes that it will continue to introduce supporting policies in the future to promote the development momentum of pharmaceutical innovation. The bank believes that the sector has opportunities for valuation repair within 2024, mainly considering: 1) there has been a large degree of disconnection in the past year, and the bank is optimistic about the chances of Hong Kong stocks recovering compared to US stocks; 2) important overseas events such as overseas licensing/mergers and acquisitions transactions are expected to continue to be implemented in 2024.
No Data